Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The Peptide Split: How GLP 1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC 157, TB 500, MOTS c, and the Wellness Grift Borrow Their Halo